Referências
Principais artigos
Hakim FE, Farooq AV. Dry eye disease: an update in 2022. JAMA. 2022 Feb 1;327(5):478-9. Resumo
Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P1-49.Texto completo Resumo
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017 Jul;15(3):276-83.Texto completo Resumo
Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based eye drops for treatment of ocular surface disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2020 Jan;127(1):128-33.Texto completo Resumo
Artigos de referência
1. Hakim FE, Farooq AV. Dry eye disease: an update in 2022. JAMA. 2022 Feb 1;327(5):478-9. Resumo
2. Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P1-49.Texto completo Resumo
3. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017 Jul;15(3):276-83.Texto completo Resumo
4. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003 Aug;136(2):318-26. Resumo
5. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000 Sep;118(9):1264-8. Resumo
6. Damato BE, Allan D, Murray SB, et al. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol. 1984 Sep;68(9):674-80.Texto completo Resumo
7. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2003 Jun;31(3):229-32. Resumo
8. Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002 Dec;86(12):1347-51.Texto completo Resumo
9. Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol. 2008 Jul;19(4):287-91. Resumo
10. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-12.Texto completo Resumo
11. Tamer C, Melek IM, Duman T, et al. Tear film tests in Parkinson's disease patients. Ophthalmology. 2005 Oct;112(10):1795. Resumo
12. D'andrea L, Montemagni M, Celenza G, et al. Is it time for a moratorium on the use of benzalkonium chloride in eyedrops? Br J Clin Pharmacol. 2022 Sep;88(9):3947-9.Texto completo Resumo
13. Nichols JJ, Sinnott LT. Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1319-28.Texto completo Resumo
14. Goebbels M. Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol. 2000 Jan;84(1):19-21.Texto completo Resumo
15. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002 Jun;966:211-22. Resumo
16. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001 Nov 7;286(17):2114-9.Texto completo Resumo
17. Kovács L, Fehér E, Bodnár I, et al. Demonstration of autoantibody binding to muscarinic acetylcholine receptors in the salivary gland in primary Sjögren's syndrome. Clin Immunol. 2008 Aug;128(2):269-76. Resumo
18. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013 Oct;11(4):246-58.Texto completo Resumo
19. Jacobi C, Wenkel H, Jacobi A, et al. Hepatitis C and ocular surface disease. Am J Ophthalmol. 2007 Nov;144(5):705-11. Resumo
20. Chronister CL. Review of external ocular disease associated with aids and HIV infection. Optom Vis Sci. 1996 Apr;73(4):225-30. Resumo
21. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999 Oct;83(10):1125-30.Texto completo Resumo
22. Prabhakaran VC, Saeed P, Esmaeli B, et al. Orbital and adnexal sarcoidosis. Arch Ophthalmol. 2007 Dec;125(12):1657-62.Texto completo Resumo
23. Liu S, Dong H, Fang S, et al. Risk of dry eye in headache patients: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):2876-85.Texto completo Resumo
24. Chuck RS, Dunn SP, Flaxel CJ, et al. Comprehensive adult medical eye evaluation preferred practice pattern®. Ophthalmology. 2021 Jan;128(1):P1-29.Texto completo Resumo
25. Lanza NL, Valenzuela F, Perez VL, et al. The matrix metalloproteinase 9 point-of-care test in dry eye. Ocul Surf. 2016 Apr;14(2):189-95. Resumo
26. Guven S. The repeatability of corneal topography measurements in severe dry eye disease. BMC Ophthalmol. 2022 Jul 15;22(1):306.Texto completo Resumo
27. Tangmonkongvoragul C, Chokesuwattanaskul S, Khankaeo C, et al. Prevalence of symptomatic dry eye disease with associated risk factors among medical students at Chiang Mai University due to increased screen time and stress during COVID-19 pandemic. PLoS One. 2022 Mar 23;17(3):e0265733.Texto completo Resumo
28. Tan LL, Sanjay S, Morgan PB. Screening for dry eye disease using infrared ocular thermography. Cont Lens Anterior Eye. 2016 Dec;39(6):442-9. Resumo
29. Gulias-Cañizo R, Rodríguez-Malagón ME, Botello-González L, et al. Applications of infrared thermography in ophthalmology. Life (Basel). 2023 Mar 8;13(3):723.Texto completo Resumo
30. Sim R, Yong K, Liu YC, et al. In vivo confocal microscopy in different types of dry eye and meibomian gland dysfunction. J Clin Med. 2022 Apr 22;11(9):2349.Texto completo Resumo
31. Aluru SV, Agarwal S, Srinivasan B, et al. Lacrimal proline rich 4 (LPRR4) protein in the tear fluid is a potential biomarker of dry eye syndrome. PLoS One. 2012;7(12):e51979.Texto completo Resumo
32. Li Y, Zhang J, Liu X, et al. Identification of inflammatory markers as indicators for disease progression in primary Sjögren syndrome. Eur Cytokine Netw. 2024 Feb 1;35(1):1-12. Resumo
33. Aljohani S, Jazzar A. Tear cytokine levels in Sicca syndrome-related dry eye: a meta-analysis. Diagnostics (Basel). 2023 Jun 27;13(13):2184.Texto completo Resumo
34. Roy NS, Wei Y, Yu Y, et al. Conjunctival HLA-DR expression and its association with symptoms and signs in the DREAM study. Transl Vis Sci Technol. 2019 Aug 21;8(4):31.Texto completo Resumo
35. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008 Sep;146(3):350-6. Resumo
36. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87.Texto completo Resumo
37. Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016 Feb 23;(2):CD009729.Texto completo Resumo
38. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003 Apr;76(4):417-20. Resumo
39. Solomon A, Rosenblatt M, Li D, et al. Doxcycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2544-57.Texto completo Resumo
40. Tamago RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991 Jan 15;51(2):672-5.Texto completo Resumo
41. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004 Feb;137(2):337-42. Resumo
42. Liu SH, Saldanha IJ, Abraham AG, et al. Topical corticosteroids for dry eye. Cochrane Database Syst Rev. 2022 Oct 21;10(10):CD015070.Texto completo Resumo
43. Tost FH, Geerling G. Plugs for occlusion of the lacrimal drainage system. Dev Ophthalmol. 2008;41:193-212. Resumo
44. Tuberville AW, Frederick WR, Wood TO. Punctal occlusion in tear deficiency syndromes. Ophthalmology. 1982 Oct;89(10):1170-2. Resumo
45. Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017 Jun 26;(6):CD006775.Texto completo Resumo
46. Tsubota K. The effect of wearing spectacles on the humidity of the eye. Am J Ophthalmol. 1989 Jul 15;108(1):92-3. Resumo
47. Shen G, Qi Q, Ma X. Effect of moisture chamber spectacles on tear functions in dry eye disease. Optom Vis Sci. 2016 Feb;93(2):158-64. Resumo
48. Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017 Feb 28;(2):CD009327.Texto completo Resumo
49. Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based eye drops for treatment of ocular surface disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2020 Jan;127(1):128-33.Texto completo Resumo
50. Geerling G, Tost FH. Surgical occlusion of the lacrimal drainage system. Dev Ophthalmol. 2008;41:213-29. Resumo
51. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005 Dec;19(4):258-63. Resumo
52. Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559.Texto completo Resumo
53. Pucker AD, Yim TW, Rueff E, et al. LipiFlow for the treatment of dry eye disease. Cochrane Database Syst Rev. 2024 Feb 5;2(2):CD015448.Texto completo Resumo
54. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren's syndrome: a randomized 12 week study. Ann Rheum Dis. 2003 Dec;62(12):1204-7.Texto completo Resumo
55. de Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019 Sep 13;9(9):CD010051.Texto completo Resumo
56. Geerling G, Sieg P. Transplantation of the major salivary glands. Dev Ophthalmol. 2008;41:255-68. Resumo
57. Barbino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003 Mar;22(2):97-101. Resumo
58. Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018 May 3;378(18):1681-90.Texto completo Resumo
59. Downie LE, Ng SM, Lindsley KB, et al. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. Cochrane Database Syst Rev. 2019 Dec 18;12(12):CD011016.Texto completo Resumo
60. Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023 Aug;252:265-74.Texto completo Resumo
61. Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023 May;130(5):516-24.Texto completo Resumo
62. Tian L, Gao Z, Zhu L, et al. Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial. JAMA Ophthalmol. 2023 Apr 1;141(4):385-92.Texto completo Resumo
63. Maskin SL, Toland C. Meibomian gland probing stimulates a proliferative epithelial response resulting in duct regeneration. Clin Ophthalmol. 2024 Mar 1:18:631-45.Texto completo Resumo
64. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea. 2010 Oct;29(10):1145-52. Resumo
65. Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015 Dec;122(12):2423-31.Texto completo Resumo
66. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014 Feb;121(2):475-83.Texto completo Resumo
67. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017 Jan;124(1):53-60.Texto completo Resumo
68. Nichols KK, Donnenfeld ED, Karpecki PM, et al. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease. Eur J Ophthalmol. 2019 Jul;29(4):394-401.Texto completo Resumo
69. Aldeyra Therapeutics, Inc. Aldeyra therapeutics completes enrollment in phase 3 clinical trial of reproxalap in dry eye disease. Jun 2024 [internet publication].Texto completo
70. Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022 Apr;129(4):379-87.Texto completo Resumo
71. Kasetsuwan N, Chantaralawan K, Reinprayoon U, et al. Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: a double-masked, randomized trial. PLoS One. 2020 Jun 5;15(6):e0234186.Texto completo Resumo
72. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med. 1993 Feb 25;328(8):584. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal